Skip to content
value.today

Optiscan Biomedical Corp.

Total raised
$129 M
6 rounds on record
Latest round
$20 M
Mar 2019
First round on record
Apr 2010
Today
Private
No later event on record

Funding rounds

6 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Optiscan Biomedical Corp.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2019$20 MNo. 6$10 to $50 million

Optiscan Biomedical Corp.: Raise no. 6, Mar 2019

Investors in this round

10 investors had bought by the notice of Mar 26, 2019: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$20 M of $25 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Cary Vance · Executive Officer, Director
  • Patrick Nugent · Executive Officer
  • Aditya Puri · Director
  • Charles Liamos · Director
  • Kenneth Abramowitz · Director
  • Paul Mieyal · Director
  • Scott Halsted · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Patrick Nugent, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 26, 2019. Read the notice at the SEC.

equitySEC
Jan 2018$15 MNo. 5$10 to $50 million

Optiscan Biomedical Corp.: Raise no. 5, Jan 2018

Investors in this round

10 investors had bought by the notice of Feb 14, 2018: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $20 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Donald Webber · Executive Officer
  • Patrick Nugent · Executive Officer
  • William Mince · Executive Officer, Director
  • Aditya Puri · Director
  • Charles Liamos · Director
  • Kenneth Abramowitz · Director
  • Paul Mieyal · Director
  • Scott Halsted · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by William Mince, Chief executive officer. Source: SEC Form D, newest notice filed Feb 14, 2018. Read the notice at the SEC.

equitySEC
May 2016$29 MNo. 4$10 to $50 million

Optiscan Biomedical Corp.: Raise no. 4, May 2016

Investors in this round

16 investors had bought by the notice of Jun 7, 2016: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$29 M of $40 M offered; $11 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Donald Webber · Executive Officer
  • Jim Causey · Executive Officer
  • Patrick Nugent · Executive Officer
  • Peter Rule · Executive Officer, Director
  • Aditya Puri · Director
  • Charles Liamos · Director
  • Kenneth Abramowitz · Director
  • Paul Mieyal · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Peter Rule, Chief executive officer. Source: SEC Form D, newest notice filed Jun 7, 2016. Read the notice at the SEC.

equitySEC
Jan 2013$31 MNo. 3$10 to $50 million

Optiscan Biomedical Corp.: Raise no. 3, Jan 2013

Investors in this round

16 investors had bought by the notice of Feb 7, 2013: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$31 M of $46 M offered; $15 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Patrick Nugent · Executive Officer
  • Peter Rule · Executive Officer, Director
  • Charles Liamos · Director
  • Paul Mieyal · Director
  • Robin Bellas · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Peter Rule, President & CEO. Source: SEC Form D, newest notice filed Feb 7, 2013. Read the notice at the SEC.

equitySEC
Oct 2012$3 MNo. 2$2 to $10 million

Optiscan Biomedical Corp.: Raise no. 2, Oct 2012

Investors in this round

2 investors had bought by the notice of Oct 29, 2012: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Peter Rule · Executive Officer, Director
  • Charles Liamos · Director
  • Paul Mieyal · Director
  • Robin Bellas · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Peter rule, President & CEO. Source: SEC Form D, newest notice filed Oct 29, 2012. Read the notice at the SEC.

optionsSEC
Apr 2010$32 MNo. 1$10 to $50 million

Optiscan Biomedical Corp.: Raise no. 1, Apr 2010

Investors in this round

12 investors had bought by the notice of Apr 14, 2010: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$32 M of $38 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Peter Rule · Executive Officer, Director
  • Charles Lianos · Director
  • Julie Eskay-Eagle · Director
  • Paul Mieyal · Director
  • Ralph Christofferson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Funds to be used for working capital.”

Signed by Ann Coppel, Sr. Legal Assistant. Source: SEC Form D, newest notice filed Apr 14, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Optiscan Biomedical Corp. chose not to state its revenue in its newest notice of a funding round (Mar 2019).

    SEC Form D · Mar 2019

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Mar 2019

That is all the official record says: Optiscan Biomedical Corp. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: the address on record now leads to another company's site.

Investors#

No investor of Optiscan Biomedical Corp. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 6 rounds above had up to 16 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Optiscan Biomedical Corp.
NameRoleNamed in
Cary VanceExecutive officerMar 2019
Patrick NugentExecutive officerMar 2019
Donald WebberExecutive officerFeb 2018
William MinceExecutive officerFeb 2018
Jim CauseyExecutive officerJun 2016
Peter RuleExecutive officerJun 2016
Aditya PuriDirectorMar 2019
Cary VanceDirectorMar 2019
Charles LiamosDirectorMar 2019
Kenneth AbramowitzDirectorMar 2019
Paul MieyalDirectorMar 2019
Scott HalstedDirectorMar 2019
William MinceDirectorFeb 2018
Peter RuleDirectorJun 2016
Robin BellasDirectorFeb 2013
Charles LianosDirectorApr 2010
Julie Eskay-EagleDirectorApr 2010
Ralph ChristoffersonDirectorApr 2010

About

Company in Hayward, United States.